Prof. Dr. Holger Lubatschowski, Head Medical Lasers, Laser Centre Hanover (Germany)
Holger has studied physics at the University of Bonn. After his PhD he moved to Hanover and became Head of Medical Laser Group at the Laser Centre Hanover (LZH). In 2001 he completed his habilitation for physics at the physics faculty of the University of Hanover and became assistant professor. Holger is now heading the department of 'Biomedical Optics' at the LZH and, since 2003 he is the CEO of Rowiak GmbH, a spin off company of the LZH, which develops ultrafast laser systems for applications in life sciences.
His major research interests are application of ultra short laser pulses in ophthalmic surgery and intra cellular surgery.

Dr. Yogeshvar N. Kalia, Senior Lecturer, Section de Sciences Pharmaceutiques, Université de Genève (Switzerland)
After completing his PhD in Chemistry at the Imperial College of Science, Technology and Medicine (London), Yogeshvar took up a postdoctoral position in the Department of Biochemistry at the University of Cambridge, where he worked on protein structure determination using NMR techniques.  In 1994, he moved to the Department of Biopharmaceutical Sciences and Pharmaceutical Chemistry at the University of California – San Francisco as a postdoctoral researcher where he began to work in the areas of transdermal drug delivery and skin biophysics.  In 1996, he moved to the School of Pharmaceutical Sciences at the University of Geneva.  His research has focused on the use of electrical techniques to characterise the skin and to facilitate molecular transport across the biological membrane as well as the development of mathematical models to provide a mechanistic understanding of these transport processes.  In 2001, he was appointed to the position of Senior Lecturer in the Laboratory of Medicinal Chemistry at the School of Pharmaceutical Sciences.  Currently, his main research activity is centred on the transdermal administration of low molecular weight and peptide therapeutics across the skin. His research is funded by public grants and through industrial collaborations.  He has published ~80 scientific papers, presented ~70 abstracts at international conferences and is a co-inventor on 4 patents.

Dr. R. Rox Anderson, professor at Harvard Medical School, adjunct professor at Massachusetts Institute of Technology (MIT) and director of the Wellman Center for Photomedicine at Massachusetts General Hospital in Boston
After graduating from MIT, Dr. Anderson received his M.D. degree from Harvard. He conceived and developed dermatologic surgery using selectively-absorbed laser pulses, which is now the preferred basis for treatment of birthmarks, pigmented lesions, tattoos, hypertrichosis and other conditions. He has made many contributions to the understanding and development of laser-tissue interactions, tissue optics, photodynamic therapy, optical diagnostics and laser based transdermal drug delivery.

Dr. Robert Strohal, Associate Professor and board-certified dermatologist and Head of the Department of Dermatology and Venerology at the Federal University Teaching Hospital Feldkirch (Austria)
After completing his thesis at the Institute of General and Experimental Pathology, University of Innsbruck Medical School, working on LE murine autoantibodies, Robert moved to the NIH, Bethesda, USA (lmmunology and Dermatology Branch, Drs S. Katz / J. Stanley) to conduct basic medical research.
Returning to Austria, he qualified as a board-certified dermatologist, and was appointed senior physician at the Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, University of Vienna School of Medicine, where he was promoted to the position of Associate Professor of Dermatology in 1999. During his sabbatical in 2001 at IDI Farmaceutici, Rome (collaboration: Dr. De-Luca), Robert worked on melanoma antigen transduced autografts as a new form of tumor vaccine. In 2002, he became Head of the Department of Dermatology and Venerology at the Federal University Teaching Hospital Feldkirch, Austria, where he also established a new biomedical research institute called VIDIT (Vorarlberg Institute for Dermatologic Investigation and Treatment), which he also heads up.
In addition to serving as an external expert for various research and funding programs associated with the European Commission (EC), Dr. Strohal is Board Secretary of the European Association of Dermato-Oncology, delegate of the Austrian Society of Dermatology and Venerology at the UEMS in Brussels, President of the Austrian Wound Association and chair of the Austrian Task Force “Biologics in Dermatology”. Dr. Strohal and his Department are involved in several multinational clinical trials (biologics and psoriasis, topical immuno-modulators and atopic eczema, adjuvant melanoma therapy) as well as leading various investigator-initiated studies and a European EC-funded concerted action.
Publishing in the field of clinical dermatology, immuno-dermatology, infection control and dermato-oncology, he has received eight national and international scientific awards. 

Dr. Jean Luc Levy, Centre Laser Dermatologique,
Marseille (France)
After obtaining a doctorate in Medicine (1984), Jean-Luc accepted a “Médaille d’or” (University Hospital Gold Medal) position in the Department of Dermatology at the University of Marseille in clinical metrology research (focusing on the field of cosmetics). In 1988, he set-up his dermatology clinic and the first private laser centre in France located at the Red Cross Hospital in Marseille.
From 1990 to 1992 he studied at ESSEC Paris and obtained an MBA specialising in the evaluation of health technology and scientific marketing. He subsequently returned to the clinic and worked to expand the laser centre at the Red Cross Hospital in Marseille; at the same time, he continued his clinical laser research on port wine stains.
In 1996, he moved to Boston and obtained a fellowship to follow the Harvard Medical Course for lasers in dermatology. Upon his return to France, he was appointed as teaching faculty for laser applications in dermatology and cosmetology at several French universities.
In 1999, he opened the “Centre Laser Dermatologique” in Marseille; he continued to perform clinical research on prototypes or new devices and the development of imaging methods to assess skin hyper-pigmentation. His research was funded by public grants and through industrial collaborations. Jean-Luc is the inventor of an ablative fractional C02 laser device manufactured by Quantel Derma (Germany) and called Exel02 (CE marked, FDA 510k pending).
In 2005, he began to collaborate with the Bodyestetic group (Barcelona, Spain); the company has developed a cream to treat pigmented spots on the skin and has also developed an electrically-based enhancement technology for transdermal cosmetic delivery.
Jean-Luc has published ~25 papers. He serves on the Editorial Boards of the Journal of Cosmetic Dermatology (US) and Journal of Cosmetic Laser Therapy (EU); he is also a reviewer for several journals in the imaging and laser dermatologic fields.